Impacts of ovarian reserve on conservative treatment for endometrial cancer and atypical hyperplasia.
Front Endocrinol (Lausanne)
; 14: 1286724, 2023.
Article
em En
| MEDLINE
| ID: mdl-38250737
ABSTRACT
Objectives:
Real-world data indicated that some endometrial atypical hyperplasia (EAH) and early endometrial carcinoma (EEC) patients of fertility preservation had a normal ovarian reserve, while some had a decreased ovarian reserve (DOR). This study was designed to investigate the effect of baseline ovarian reserve on the treatment of EAH and EEC patients who ask for preservation of fertility.Methods:
This was a prospective cohort study conducted at a single university-affiliated fertility center. A total of 102 EAH and EEC patients who received fertility-preserving treatment between March 2019 and August 2020 were included and divided into a DOR group (n=22) and a non-DOR group (n=80).Results:
The 32-week CR rate of the non-DOR group was significantly higher than that of the DOR group (60.3% vs. 33.3%, P =0.028). The DOR group had a longer treatment duration to achieve CR than the non-DOR group (40.07 vs. 29.71 weeks, P=0.008, HR 0.54, 95% CI 0.36-0.86). Multivariate logistic regression analyses demonstrated that DOR (OR 0.35, 95% CI 0.13-0.99, P=0.049) and BMI ≥25 kg/m2 (OR 0.40, 95% CI 0.17-0.92, P=0.031) were negatively associated with 32-week CR.Conclusions:
Decreased baseline ovarian reserve is negatively correlated with the efficacy of fertility-preserving treatment in EAH and EEC patients, as this group has a lower CR rate and a longer treatment duration to achieve CR than those without DOR.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Endométrio
/
Hiperplasia Endometrial
/
Reserva Ovariana
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article